PBPing Bai

Ping Bai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ping Bai has a total of 121 co-authors. Here are the top co-authors by number of shared publications:

  • Changning Wang

    Harvard Medical School

    20 shared publications
  • Yan Liu

    Athinoula A. Martinos Center for Biomedical Imaging Department of Radiology Massachusetts General Hospital, Harvard Medical School Charlestown Massachusetts USA

    9 shared publications
  • Yanting Zhou

    Sichuan University

    9 shared publications
  • Can Zhang

    Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, United States

    8 shared publications
  • Hui Meng

    6 shared publications
  • Rudolph E. Tanzi

    Genetics and Aging Research Unit McCance Center for Brain Health Mass General Institute for Neurodegenerative Disease Department of Neurology Massachusetts General Hospital Harvard Medical School 114 16th Street Charlestown MA 02129 USA

    6 shared publications

Latest Publications

  • Development of a Potent and Isoform-Selective HDAC11 Inhibitor with Anti-Tumor Efficacy against Non-Small Cell Lung Cancer

    by Xinyu Yang, Xin Li, Rui Huang, Yanting Zhou, Hongyan Li, Pan Yao, Yue Hu, Yuhang Liu, Changning Wang, Ping Bai

    Targeting histone deacetylase 11 (HDAC11) represents a promising therapeutic strategy, yet developing selective inhibitors for solid tumors remains a formidable challenge. Herein, we describe the rational lead optimization of a novel series of indole-based hydroxamic acids. Guided by our previous lead PB94, a systematic, multiparameter optimization of the core, linker, and cap regions was conducted to specifically target HDAC11. This campaign yielded compound YP200, which incorporates a precisely positioned secondary amine linker and an adamantane surface-recognition cap. YP200 exhibited exceptional HDAC11 inhibitory potency (IC50 = 0.058 ± 0.01 μM) and good selectivity (>103-fold) over other HDACs. Furthermore, YP200 demonstrated good in vivo anti-tumor efficacy in a non-small cell lung cancer (NSCLC) patient-derived xenograft model. These findings validate YP200 as a promising HDAC11-targeted therapeutic candidate, significantly expanding the therapeutic arsenal for solid tumors.

  • Open Access

    Development of a novel HDAC6 PET imaging agent uncovers associations between HDAC6 overexpression and neuroinflammation in depression

    by Yanting Zhou, Yuheng Zou, Xiao Zhong, Hongyan Li, Jingyi Yang, Hui Meng, Weiyao Xie, Pan Yao, Xiaoai Wu, Huawei Cai, et al.


  • Development and Preclinical Evaluation of Novel F-18-Labeled Dihydropyrazole RIPK1 PET Tracers for Neuroinflammation Imaging

    by Hongyan Li, Zeyi Qin, Yanting Zhou, Hui Meng, Weiyao Xie, Pan Yao, Xinyu Yang, Huawei Cai, Lin Li, Changning Wang, et al.

    Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation and cell death, making it a promising target for diagnosing neurodegenerative diseases. In this study, we developed and evaluated two novel dihydropyrazole-based PET tracers, [18F]PB833 and [18F]PB830, through structural optimization of dihydropyrazole-based inhibitors. Both tracers demonstrated good blood-brain barrier penetration in rodents. Notably, [18F]PB830 showed superior brain uptake, binding specificity, and metabolic stability. In a mouse model of neuroinflammation, the [18F]PB830 PET signal was significantly elevated, which correlated with increased RIPK1 expression confirmed by immunofluorescence. Furthermore, [18F]PB830 showed robust brain uptake in nonhuman primates with a peak SUV of 2.6, indicating the translational potential. Our findings establish [18F]PB830 as a promising PET radioligand for noninvasive assessment of neuroinflammation and for preclinical studies of neurodegenerative diseases.


  • Open Access

    Development of Carbon‐11 Labeled Pyrimidine Derivatives as Novel Positron Emission Tomography (PET) Agents Enabling Brain Sigma‐1 Receptor Imaging

    by Ping Bai, Ashley Gomm, Chi‐Hyeon Yoo, Prasenjit Mondal, Fleur Marie Lobo, Hui Meng, Yanting Zhou, Weiyao Xie, Hsiao‐Ying Wey, Rudolph E. Tanzi, et al.

    The sigma‐1 receptor (σ1R) is a stress‐activated chaperone protein that has emerged as a significant therapeutic target for neurodegenerative disorders. Developing effective positron emission tomography (PET) imaging probes targeting σ1R is crucial for visualizing its distribution and function in the brain, as well as facilitating related drug development. In this study, two novel 11C‐labeled PET probes based on the structure of a potent σ1R ligand Lan‐0101 are designed and synthesized. PET imaging studies in mice reveal that [11C]CNY‐01 exhibits good brain uptake and binding specificity. Subsequent evaluation in non‐human primates further demonstrates that [11C]CNY‐01 displays favorable brain penetration, slow clearance kinetics, and characteristics of irreversible binding to its target in blockage experiments. To assess the clinical potential of the probe, both in vitro experiments and in vivo PET imaging using [11C]CNY‐01 are conducted in Alzheimer's disease (AD) transgenic mouse models. These studies reveal a significant decrease in σ1R expression in the brain under conditions of AD amyloid pathology and microglial activation, highlighting the probe's sensitivity to disease‐related receptor changes. This work establishes [11C]CNY‐01 as a promising tool for investigating the relationship between σ1R and neurological disorders, potentially advancing the understanding of σ1R's role in disease pathophysiology and therapeutic interventions.


  • Open Access

    HDAC11 displays neuropathological alterations and offers as a novel drug target for Alzheimer's disease

    by Ping Bai, Prasenjit Mondal, Yan Liu, Ashley Gomm, Claire Suen, Liuyue Yang, Biyue Zhu, Haoqi Sun, Chongzhao Ran, Shiqian Shen, et al.

    INTRODUCTION: Alzheimer's disease (AD) is characterized by amyloid pathology and neuroinflammation, leading to cognitive decline. Targeting histone deacetylase‐11 (HDAC11) offers a novel therapeutic strategy due to its role in immune regulation.METHODS: We conducted neuropathological analyses on human AD post mortem brain tissues and 5xFAD transgenic mice. We developed PB94, a brain‐permeable HDAC11‐selective inhibitor, and assessed its effects using live‐animal imaging and behavioral studies.RESULTS: HDAC11 was significantly upregulated in AD brains, correlating with amyloid pathology and neuroinflammatory markers. PB94 treatment reduced amyloid burden and neuroinflammation, improving cognitive function in 5xFAD mice.DISCUSSION: Our findings highlight HDAC11 as a promising drug target for AD. PB94's ability to reduce amyloid pathology and neuroinflammation suggests its potential as an effective therapeutic. This study supports further exploration of HDAC11 inhibition as a treatment strategy for AD.Highlights: Histone deacetylase‐11 (HDAC11) is significantly upregulated in Alzheimer's disease (AD) brains and colocalizes with amyloid pathology and neuroinflammatory markers. Novel brain‐permeable HDAC11‐selective inhibitor PB94 demonstrates promising therapeutic potential for AD treatment. PB94 treatment reduces amyloid burden and neuroinflammation in AD mouse models, confirmed by live imaging studies. HDAC11 inhibition enhances microglial phagocytosis of amyloid beta proteins and modulates inflammatory cytokine levels. PB94 treatment improves cognitive function in AD mouse models while showing favorable brain penetration and selectivity.


  • Molecular Imaging Reveals Antineuroinflammatory Effects of HDAC6 Inhibition in Stroke Models

    by Yanting Zhou, Chen Li, Rui Wu, Honghai Yin, Gang Liu, Hui Meng, Weiyao Xie, Vishal C. Birar, Changning Wang, Xiaoai Wu, et al.

    Ischemic stroke is a devastating disease that causes neuronal death, neuroinflammation, and other cerebral damage. However, effective therapeutic strategies for ischemic stroke are still lacking. Histone deacetylase 6 (HDAC6) has been implicated in the pathogenesis of ischemic stroke, and the pharmacological inhibition of HDAC6 has shown promising neuroprotective effects. In this study, we utilized positron emission tomography (PET) imaging with the HDAC6-specific radioligand [18F]PB118 to investigate the dynamic changes of HDAC6 expression in the brain after ischemic injury. The results revealed a significant decline in [18F]PB118 uptake in the ipsilateral hemisphere on the first day after ischemia, followed by a gradual increase on days 4 and 7. To evaluate the therapeutic potential of HDAC6 inhibitors, we developed a novel brain-permeable and potent HDAC6 inhibitor, PB131, and assessed its neuroprotective effects in an ischemic stroke mouse model. PET imaging studies demonstrated that PB131 treatment alleviated the decline in [18F]PB118 uptake and reduced the infarct size in middle cerebral artery occlusion mice. Furthermore, PET imaging with the TSPO-specific radioligand [18F]FEPPA revealed that PB131 significantly suppressed neuroinflammation in the ischemic brain. These findings provide insights into the dynamic changes of HDAC6 in ischemic stroke and the potential of HDAC6 inhibitors as novel therapeutic agents for this condition.


  • PET imaging assist investigation of HDAC6 expression change in MDD and evaluating antidepressant efficacy of a newly developed HDAC6 inhibitor

    by Xiao Zhong, Xiaoai Wu, Yanting Zhou, Rui Wu, Jingyi Yang, Honghai Yin, Hui Meng, Weiyao Xie, Gang Liu, Changning Wang, et al.


  • Design, synthesis, and preclinical evaluation of 11C/18F-labeled inhibitors for RIPK1 PET imaging

    by Tianwen Luo, Yanting Zhou, Rui Wu, Honghai Yin, Weiyao Xie, Hui Meng, Chenyao Zhao, Yanli Wang, Yongle Wang, Leyi Kang, et al.


  • Open Access

    Development of a New Positron Emission Tomography Imaging Radioligand Targeting RIPK1 in the Brain and Characterization in Alzheimer's Disease

    by Ping Bai, Yu Lan, Yan Liu, Prasenjit Mondal, Ashley Gomm, Yulong Xu, Yanli Wang, Yongle Wang, Leyi Kang, Lili Pan, et al.

    Targeting receptor‐interacting protein kinase 1 (RIPK1) has emerged as a promising therapeutic stratagem for neurodegenerative disorders, particularly Alzheimer's disease (AD). A positron emission tomography (PET) probe enabling brain RIPK1 imaging can provide a powerful tool to unveil the neuropathology associated with RIPK1. Herein, the development of a new PET radioligand, [11C]CNY‐10 is reported, which may enable brain RIPK1 imaging. [11C]CNY‐10 is radiosynthesized with a high radiochemical yield (41.8%) and molar activity (305 GBq/µmol). [11C]CNY‐10 is characterized by PET imaging in rodents and a non‐human primate, demonstrating good brain penetration, binding specificity, and a suitable clearance kinetic profile. It is performed autoradiography of [11C]CNY‐10 in human AD and healthy control postmortem brain tissues, which shows strong radiosignal in AD brains higher than healthy controls. Subsequently, it is conducted further characterization of RIPK1 in AD using [11C]CNY‐10‐based PET studies in combination with immunohistochemistry leveraging the 5xFAD mouse model. It is found that AD mice revealed RIPK1 brain signal significantly higher than WT control mice and that RIPK1 is closely related to amyloid plaques in the brain. The studies enable further translational studies of [11C]CNY‐10 for AD and potentially other RIPK1‐related human studies.


  • Molecular Imaging of Alzheimer’s Disease-Related Sigma-1 Receptor in the Brain via a Novel Ru-Mediated Aromatic 18F-deoxyfluorination Probe

    by Ping Bai, Frederick A. Bagdasarian, Yulong Xu, Yanli Wang, Yongle Wang, Ashley Gomm, Yanting Zhou, Rui Wu, Hsiao-Ying Wey, Rudolph E. Tanzi, et al.

    Sigma-1 receptor (σ1R) is an intracellular protein implicated in a spectrum of neurodegenerative conditions, notably Alzheimer's disease (AD). Positron emission tomography (PET) imaging of brain σ1R could provide a powerful tool for better understanding the underlying pathomechanism of σ1R in AD. In this study, we successfully developed a 18F-labeled σ1R radiotracer [18F]CNY-05 via an innovative ruthenium (Ru)-mediated 18F-deoxyfluorination method. [18F]CNY-05 exhibited preferable brain uptake, high specific binding, and slightly reversible pharmacokinetics within the PET scanning time window. PET imaging of [18F]CNY-05 in nonhuman primates (NHP) indicated brain permeability, metabolic stability, and safety. Moreover, autoradiography and PET studies of [18F]CNY-05 in the AD mouse model found a significantly decreased brain uptake compared to that in wild-type mice. Collectively, we have provided a novel 18F-radiolabeled σ1R PET probe, which enables visualizing brain σ1R in health and neurological diseases.